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Enoxacin is a fluorinated quinolone with potential clinical use in the treatment of serious infections.
Twenty-three patients (age, 19 to 87 years) with different degrees of renal function, including a group
undergoing chronic hemodialysis, received enoxacin (400 mg) by intravenous infusion (1 h). Blood samples
were collected before infusion; at the end of infusion; and at 5, 10, 20, 30, 45, 60, 90, and 120 min and 3, 4,
6, 12, 18, 24, 48, and 72 h after infusion. Enoxacin and oxoenoxacin concentrations were measured by
high-pressure liquid chromatography. Pharmacokinetic parameters (mean standard deviation) were
calculated by using a noncompartmental PK model according to creatinine clearances (in milliliters per
minute). Total clearance of enoxacin decreased from 4.95 + 1.16 ml/min per kg in the group with normal
creatinine clearance to 0.76 0.21 ml/min per kg in the patients with severe renal failure (creatinine clearance,
<15 ml/min), whereas the elimination half-life increased from 4.5 + 1.0 to 20 5 h, respectively. The
elimination of oxoenoxacin (the main metabolite of enoxacin) in urine was markedly decreased when creatinine
clearance was <15 ml/min. Hemodialysis removed an insignificant amount of enoxacin and oxoenoxacin. These
data indicate that as creatinine clearance fails below 30 ml/min, the daily enoxacin dose should be reduced by
half. During prolonged administration of enoxacin to patients with creatinine clearances of <30 ml/min, the
accumulation of oxoenoxacin might lead to unexpected side effects.
The family ofDNA gyrase inhibitors comprises two types
of molecules: those which inhibit subunit A (quinolones) and
those which inhibit subunit B (coumermycin, novobiocin,
chlorobiocin).
The "first generation" of quinolones comprise nalidixic
acid, cinoxacin, pipemidic acid, oxolinic acid, flumequine,
and acrosoxacin and are indicated primarily for the treat-
ment of urinary tract infections. The "second generation"
comprises recently developed molecules of clinical interest
in the treatment of systemic infections (pefloxacin, norflox-
acin, enoxacin, ofloxacin, ciprofloxacin, fleroxacin, lome-
floxacin). These agents are characterized by their enhanced
in vitro activities against gram-negative aerobes and im-
proved intestinal absorptions.
Enoxacin is a new fluorinated quinolone with high in vitro
activity. Available studies indicate that it is effective in the
management of infections caused by susceptible organisms
(4, 9).
The influence of renal failure on the pharmacokinetics of
enoxacin given orally has been studied previously (1, 7), but
not following intravenous (i.v.) administration. Further-
more, the disposition of the major metabolite of enoxacin,
oxoenoxacin, in patients with renal impairment has not been
described.
The purpose of this study was to evaluate the pharmaco-
kinetics of i.v. administered enoxacin and its oxometabolite
in patients with different degrees of renal impairment.
* Corresponding author.
MATERIALS AND METHODS
The protocol for this study followed the guidelines of the
Declaration of Helsinki and was reviewed by the local
ethical committee. Each patient gave informed consent.
Patients. Twenty-three patients (age, 19 to 87 years) with
various degrees of renal impairment were enrolled in this
study. Patients were categorized prior to the administration
of enoxacin into five classes according to the measured
creatinine clearances, which were based on 24-h urine
collections. The following classes were defined (number of
patients): 1, patients on chronic hemodialysis (four patients);
2, creatinine clearance, <15 ml/min (four patients); 3, creat-
inine clearance, 15 to 30 ml/min (six patients); 4, creatinine
clearance, 30 to 60 ml/min (four patients); 5, creatinine
clearance, >60 ml/min (five patients).
The exclusion criteria were pregnant or lactating women;
hepatic enzymes twice the upper limit of normal or serum
bilirubin levels of >1 mg/dl; patients with an allergy to any
quinolone agent; patients who were on concomitant antibac-
terial therapy or who received any antibiotic during the
previous week; and patients who weighed less than 40 kg.
Experimental design. Patients received a single 400-mg
dose of enoxacin (supplied as 200-mg/ml ampoules [batch
RM 830567] by Parke Davis & Co., Warner-Lambert, De-
troit, Mich.) diluted in 100 ml of 5% glucose in water. The
dose was given as a constant-rate infusion over 1 h through
the antecubital vein by using an infusion pump. All four
patients in the dialysis group were studied twice while they
were off dialysis; three of these patients were also studied
during dialysis. The interval between studies done while
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1492 VAN DER AUWERA ET AL.
TABLE 1. Demographic characteristics of patients
examined in study
Group Median ae No. of Median(no. of mage no Median wt creatinine
patients) (yr [range]) of women (kg range]) clearance(ml/min [range])
1 (4) 56 (19-83) 1, 4 60.5 (52.5-80.8) 5 (0-10)
2 (4) 50 (36-79) 1, 3 76.1 (63-146) 9 (9-14.9)
3 (6) 66 (57-87) 5, 1 65 (58.8-104) 23.2 (18-27)
4 (4) 79 (66-83) 2, 2 73.1 (68.7-88) 41 (34-61)
5 (5) 54 (26-68) 1, 4 73.7 (48-132) 82.8 (67-146)
patients were on and off dialysis was at least 24 h. Dialysis
was initiated 3 h after drug administration.
Clinical and laboratory data. Base-line clinical and labora-
tory data were taken within 24 h prior to the start of the
study and again on completion of the study. The following
data were obtained: patient medical history and physical
examination; 02-microglobulin (serum and urine); complete
blood count with differential; serum urea and creatinine;
serum glutamic oxalacetic transaminase, serum glutamic
pyruvic transaminase, total bilirubin, and alkaline phos-
phatase; total serum protein or serum albumin; erythrocyte
sedimentation rate; serum electrolytes; and creatinine clear-
ance.
Blood sampling times. Blood samples were obtained before
drug administration and at 5, 10, 30, 45, 60, 90, and 120 min
5
5 0.5
and 3, 4, 6, 12, 18, 24, 48, and 72 h after drug administration.
After clotting, the blood samples were centrifuged and the
serum was stored at -20°C.
Urine sampling times. Urine was collected from each
patient (excluding dialysis patients) beginning at the time of
dosing. The collections were taken at 0 to 4, 4 to 8, 8 to 12,
12 to 24, 24 to 48, and 48 to 72 h postdosing. The volume of
urine from each collection period was noted, and a 50-ml
portion was stored at -20°C until the quinolone concentra-
tion in the sample was analyzed.
Dialysate sampling times. Portions of the dialysate were
obtained at time zero and at 30, 60, 90, 120, 150, 180, 210,
and 240 min after the beginning of hemodialysis.
Assay. The concentrations of enoxacin and oxoenoxacin
were measured by high-pressure liquid chromatography.
Standards (enoxacin [potency, 918 mg/g] and oxoenoxacin
[potency, 1,000 mg/g], 5, 2, 1, 0.5, 0.25, and 0.12 mg/liter)
and controls (enoxacin, 8 and 0.8 mg/liter; oxoenoxacin, 4
and 0.4 mg/liter) were prepared in a fashion similar to that
described above for test samples, from pooled sera (serum
assay), and in phosphate buffer (urine and dialysis fluid
assays). An external serum control sample was obtained
from Warner-Lambert.
All chemicals used in this study were of analytical high-
pressure liquid chromatography grade. Enoxacin, oxoenox-
acin, and norfloxacin (internal standard) reference powders
were obtained from Warner-Lambert. Water was passed
through a water purification system (Millipore Corp.). Phos-
~03
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FIG. 1. Mean concentrations of enoxacin (a) and oxoenoxacin (b) in serum following the i.v. administration of enoxacin (40 mg) in the five
groups of patients investigated. Symbols: V, group 1 (off dialysis); V, group 2; A, group 3; A, group 4; 0, group 5.
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PHARMACOKINETICS OF ENOXACIN 1493
TABLE 2. Enoxacin pharmacokinetic parameters according to degree of renal impairmenta
Pharmacokinetic Group 1 Group 2 Group 3 Group 4 Group 5
parameterb (<15 ml/min,c (<15 ml/min) (15-30 ml/min) (30-60 ml/min) (>60 ml/min)hemodialysis)
CLT (ml/min per kg) 1.72 ± 0.58 0.99 + 0.21 1.32 ± 0.36 3.98 ± 2.90 4.95 + 1.16
(0.92-2. l)d,e (0.76-1.26)df.g (0.91-4.68)h (1.12-7.41) (3.70-6.36)
CLR (ml/min per kg) ND' 0.16 ± 0.006 0.47 ± 0.17 1.00 ± 1.00 2.22 ± 0.57
(0.10-0.16)d (0.31-0.76)d (0.40-2.16Y (1.57-2.93)
CLNR (ml/min per kg) ND 0.84 ± 0.16 0.90 ± 0.33 2.55 ± 2.39 3.00 ± 0.93
(0.64-1.02)d (0.54-3.92)' (0.72-5.25Y(2.13)4.33)k
Vs, (liters/kg) 2.68 ± 1.53 1.78 ± 0.68 1.66 ± 0.53 2.34 ± 1.50 1.59 + 0.41
(1.36-4.74) (1.15-2.71) (1.18-2.60) (1.46-4.59) (1.14-2.13)
t1l/2z (h) 19.86 ± 14.16 19.77 ± 5.50 12.98 ± 4.33 8.40 ± 4.03 4.47 ± 0.96(9.8-36.5)d (13.33-26.65) (6.60-16.12)d (4.75-13.86) (3.57-5.92)
Cmax (mg/liter) 5.66 ± 1.92 5.04 ± 1.41 7.13 ± 2.34 4.76 ± 1.61 6.97 ± 1.75
(3.82-7.77) (2.99-6.13) (4.28-9.94) (3.06-6.45) (4.0-8.16)
C12 (mg/liter) 0.90 ± 0.18 1.60 ± 0.62 1.86 ± 0.50 0.76 ± 0.65 0.68 ± 0.20
(0.78-1.03) (1.07-2.31)d (1.31-2.60)d,g (0.24-1.65) (0.40-0.94)
a Values are means ± standard deviations; ranges are given in parentheses.
b Abbreviations: CLr, total clearance; CLR, renal clearance; CLNR, nonrenal clearance; Vs,, volume of distribution at steady state; tl/2,,, half-life at the
terminal elimination phase; Cmax, maximum concentration of exoxacin in serum; C12, concentration of exoxacin in serum at 12 h.
c Values are creatinine clearance.
d Significantly different (P < 0.05) from group 5.
e Not significantly different from group 5 if data for patient 11 in group 3 are excluded from the statistical computations.
f Significantly different (P < 0.05) from group 5 if data for patient 11 in group 3 are excluded from the statistical computations.
g Significantly different (P < 0.05) from group 5.
h Data for patient 11 in group 3 were excluded from statistical computations (P < 0.05 versus group 5).
'ND, Not detectable.
Urine collections were adequate to estimate this parameter in e ily three patients in this group.
k Urine collections were adequate to estimate this parameter in -;ly four patients in this group.
1 Data for patient 11 in group were excluded from statistical computations.
phate buffer (0.2 M; pH 7.4) was prepared from monobasic
and dibasic sodium phosphate (E. Merck AG, Darmstadt,
Federal Republic of Germany). Other chemicals included
citric acid (Merck), ammonium perchlorate (99.8%; Ega-
Chemie, Steinheim, Federal Republic of Germany), tetrabu-
tylammonium hydroxyde (20% in water; Merck), acetonitrile
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FIG. 2. Relation between creatinine clearance (CLCR) and enox-
acin total clearance (CLT) [CLT = (3.1 x CLCR) + 88.0; P < 0.05]
(a), renal clearance (CLR) (CLR = 1.7 x CLCR; P < 0.05) (b),
nonrenal clearance (CLNR) [CLNR = (1.54 x CLCR) + 79.8; P <
0.05] (c), and slope of the terminal elimination phase (X,) [X, =
(0.0012 X CLCR) + 0.04; P < 0.05] (d).
(70 to 72%; Merck), and perchloric acid (D = 1.67, 70%;
Merck). The chromatographic system (Waters Associates,
Inc., Milford, Mass.) used in this study consisted of a model
510 pump, a model 710B WISP autosampler, a Lambda-
Max-481 variable-wavelength detector set at 340 nm, a data
module recorder integrator, and a programmable system
controller. The column (12.5 cm by 4.6 mm) was packed
with C18 reversed-phase (LiChrospher, 10ORP-18e, 5 ,um;
Merck). The mobile phase was 0.1 M citric acid-acetonitrile
(86:14) with 1.3 ml of tetrabutylammonium hydroxide and
0.9 g of NH4C104 at a flow rate of 1 ml/min at room
temperature.
(i) Serum assay. A total of 20 [lI of internal standard (100
mg/liter in 0.2 M phosphate buffer) was added to 0.2 ml of
serum and vortexed. A total of 50 pul of perchloric acid-
acetonitrile (1:4; vol:vol) was added, vortexed, and centri-
fuged for 2 min at 10,000 x g. Duplicate portions of 20 to 30
pul of the clear supernatant were injected onto the column.
(ii) Urine assay. Portions of urine were diluted 50 times in
the mobile phase, after centrifugation at 10,000 x g for 2
min, and duplicate portions of 30 pl of the clear supernatant
were injected onto the column.
(iii) Dialysis fluid assay. A total of 30 ,ul of dialysis fluid was
injected onto the column. Standards and controls were
tested in duplicate (two different extractions or preparations)
during each assay run. Patient samples, standards, and
controls were placed at random order into the autosampler
(WISP; Waters Associates).
Performance of the assays. The assays described here were
linear to at least 10 mg/liter for both enoxacin and oxoenox-
acin. The sensitivities were 0.05 mg/liter for both enoxacin
and oxoenoxacin. For the three fluids assayed, interday
assay variabilities ranged from 4 to 10% for enoxacin and 2
to 4% for oxoenoxacin, depending on the concentration
-3
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1494 VAN DER AUWERA ET AL.
TABLE 3. Urinary recoveries of enoxacin and oxoenoxacin
Recovery' ConcnDrug and group Period (h) Recovery (mg/liter)
(no. of patients) considered
Mean Range Mean Range
1.5-3.6
1.5-2.7
0.8-2.3
2.4-4.3
3.1-4.2
4.2-4.2
6.7-18.6
3.5-11.5
2.5-6.1
1.6-19.1
2.5-7.0
1.7-10.3
0.2-3.5
22.6-39.7
2.5-15.3
1.9-8.5
1.7-5.3
2.3-5.4
2.5-5.6
17.7-34.7
19.2-31.7
5.9-15.1
4.8-10.2
4.7-8.5
0.8-2.6
0.6-1.8
36.2-56.1
0-3.5
0-1.7
0-0.8
0-0.4
0-0.3
0-0.6
0-5.5
0.4-5.7
1.4-4.1
0-28.9
0-14.0
0-29.4
0-13.5
0-71.2
3.5-22.0
6.1-10.1
5.1-6.3
0.4-8.8
0.3-13.7
0-14.8
20.7-62.3
17.1-27.6
6.6-19.8
0-12.4
0-12.0
0-4.7
0-0.8
24.8-62.7
21.8 17.3-26.5
17.8 14-23.9
15.9 12.5-18.7
11.1 10.2-11.6
8.7 7.1-10.5
6.8 5.6-8.5
77.0 21.5-139.5
57.8 14.6-116.7
62.1 11.9-130.0
48.4 11.9-72.5
22.2 6.7-51.7
9.1 1.1-19.2
108.0 38.8-245.1
70.3 31.6-136.8
33.2 21.3-39.7
15.7 7.1-25.2
20.4 6.7-33.5
NA
246.0 64.3-330.0
153.1 42.0-301.7
67.1 28.5-161.1
43.6 24.0-96.8
8.4 1.1-21.1
3.3 1.5-4.3
2.9 0-7.0
2.6 0-7.0
2.6 0-7.0
0.1 0-0.3
0.1 0-0.2
0.4 0-0.9
18.5
16.6
22.7
20.1
11.6
5.5
28.8
26.3
17.5
10.5
7.6
5.0
48.4
36.3
17.7
16.5
3.2
0.1
0.5-57.0
7.1-39.0
0-47.4
0-35.0
0-28.0
0-14.2
6.2-88.1
10.0-59.8
8.2-28.9
0.3-20.1
0.3-13.3
0-7.1
17.6-68.3
8.2-98.8
0-58.9
0-37.2
0-9.4
0-0.3
tested. Mean analytical recoveries were 89% for enoxacin
and 80% for oxoenoxacin.
Pharmacokinetics and statistical analysis. Serum concen-
tration-time data were analyzed by using noncompartmental
pharmacokinetic methods (2). The areas under the zero and
first moment of the serum concentration-time curves (AUCs)
were calculated by the linear trapezoidal rule method. The
terminal slope was determined by fitting an open two-
compartment body model to data for serum by using ex-
tended least-squares regression, with the variance modeled
as yPWR, where Y is the predicted drug concentration, and
PWR is a fitted parameter constrained to be between 1 and 3
(MK model; Elsevier Biosoft, Cambridge, United King-
dom). Residual areas were calculated by dividing the last
measurable concentration of enoxacin or oxoenoxacin by
the respective terminal slope. Major pharmacokinetic pa-
rameters were calculated by using standard equations cor-
rected for an i.v. infusion (2). Enoxacin and oxoenoxacin
renal clearances were calculated as follows Ae-24/AUCO24,
where Ae,>24 is the amount of drug or metabolite excreted
unchanged in the urine for the collection period from 0 to 24
h and AUCO24 is the area under the serum enoxacin or
oxoenoxacin concentration-time curve from 0 to 24 h. Non-
renal clearance of enoxacin was calculated as the difference
between total and renal clearances.
The pharmacokinetic parameters obtained in each group
were compared by the Peritz F test (3). Correlations were
performed by using unweighted least-squares regression
analysis. The intercept was forced through zero for correla-
tions between creatinine and enoxacin or oxoenoxacin renal
clearance.
RESULTS
Enoxacin pharmacokinetics. Table 1 summarizes the de-
mographic characteristics of the patients examined in this
study. None of the patients experienced side effects or
toxicity which could be attributed to enoxacin. Figure 1
depicts mean serum concentration-time curves for enoxacin
for each of the five patient groups studied. Overall, reduced
renal function was associated with higher and more pro-
longed enoxacin concentrations.
Table 2 summarizes the pharmacokinetics of enoxacin in
each of the five patient groups. Average peak concentrations
in each group ranged between 4.7 and 7.1 mg/liter; there was
no statistically significant difference between groups. At 12
h, enoxacin concentrations in serum were significantly
higher in groups 2 and 3 than those observed in group 5.
Figure 2 depicts the linear correlation between creatinine
clearance and total, renal, and nonrenal enoxacin clearances
and the slope of the terminal elimination phase (Xe). Patient
groups with creatinine clearances lower than 30 ml/min had
mean values for total enoxacin clearance approximately
one-third or less of those observed in group 5 patients
(creatinine clearance, >60 ml/min); the total enoxacin clear-
ance in groups 1 to 3 was significantly less than that observed
in group 5 patients (Table 2; P < 0.05). The reduction in total
clearance in these groups was largely due to reduced renal
enoxacin clearance; however, nonrenal enoxacin clearance
in patients with a creatinine clearance of less than 15 ml/min
(group 2) was significantly less than that observed in group 5
patients (Table 2; P < 0.05). Interpatient variability was
notably large in some patient groups; one patient in group 3
had total and nonrenal enoxacin clearances larger than the
calculated mean value plus six times the standard deviation
for group 3 without this patient.
Changes in enoxacin clearance were reflected in changes
Enoxacin
2 (4)
3 (6)
4 (3)
5 (4)
Oxoenoxacin
2 (4)
3 (6)
4 (5)
5 (4)
0-4
4-8
8-12
12-24
24-48
48-72
0-72
0-4
4-8
8-12
12-24
24-48
48-72
0-72
0-4
4-8
8-12
12-24
24-48
48-72
0-48
0-4
4-8
8-12
12-24
24-48
48-72
0-72
0-4
4-8
8-12
12-24
24-48
48-72
0-72
0-4
4-8
8-12
12-24
24-48
48-72
0-72
0-4
4-8
8-12
12-24
24-48
48-72
0-72
0-4
4-8
8-12
12-24
24-48
48-72
0-72
2.6
2.0
1.4
3.5
3.7
4.2
12.5
6.4
3.6
6.2
5.3
5.2
2.2
28.9
9.2
4.1
3.3
4.2
4.1
NAb
23.6
23.1
10.6
7.4
6.4
1.7
1.1
48.1
1.3
1.0
0.7
0.1
0.1
0.1
3.5
6.1
8.3
7.9
19.3
0.7
0.6
40.1
8.5
6.7
5.1
5.9
5.2
4.4
37.5
21.1
9.0
7.4
7.3
1.8
0.3
46.8
I Recovery of enoxacin is expressed as percentage of dose. Recovery of
oxoenoxacin is expressed in milligrams.
b NA, Not available.
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TABLE 4. Oxoenoxacin pharmacokinetic parameters according to renal impairment'
Pharmacokinetic Group 1 Group 2 Group 3 Group 4 Group 5parameterb
Cm,, (mg/liter) 1.78 + 0.63 1.24 ± 0.52 0.95 ± 0.27 0.54 ± 0.17 0.71 ± 0.37
(1.18-2.52) (0.78-1.81) (0.5-1.17) (0.36-0.74) (0.36-1.31)
(n 4)C (n =3) (n =6) (n =4) (n = 5)
C12 (mg/liter) 1.20 ± 0.09 1.02 ± 0.28 0.69 ± 0.40 0.31 ± 0.16 NDe
(1.13-1.26) (0.74-1.41) (0.20-1.17) (0.13-0.41)
(n =2)C (n 4)d (n =6)d (n 3)d
AUCO_24 (mg. h/liter) 44.06 ± 31.0 24.11 ± 7.85 17.23 ± 7.62 7.83 ± 3.29 2.81 ± 1.16
(22.30-79.51)d (17.07_35.35)C (6.64-26.59)d (4.08-10.23)d (1.20-4.24)
CLR (ml/min per kg) 0.11 ± 0.09 0.45 ± 0.35 1.39 ± 1.51 4.00 ± 3.36(0.03-0.22)d (0.09-1.12)d (0.51-3.13) (2.0-9.02)f
a Values are means ± standard deviations; values in parentheses are ranges.
b Abbreviations: Cn,,x maximum concentration of oxoenoxacin in serum; C12, concentration of enoxacin in serum at 12 h; AUCO24, AUC from 0 to 24 h; CLR,
renal clearance.
c Significantly different from groups 4 and 5.
d Significantly different from group 5.
eND, Not detectable.
f Data for patient 21 in group 5 were excluded from the statistical computations.
in the half-life of the terminal elimination phase (Xi). The
terminal half-life was statistically significantly prolonged in
groups 1 to 3 (mean values, 13.0 to 19.9 h) compared with
that in group 5 (4.5 h) (P < 0.05); interpatient variability was
considerably large and did not appear to be related to the
degree of decrement in renal function. The steady-state
volume of distribution was not different between groups
(Table 2). Table 3 shows the urinary excretion of enoxacin.
Average urinary recovery in each group ranged from 12.5 to
48.1% of the dose and decreased with worsening renal
dysfunction.
Oxoenoxacin pharmacokinetics. Table 4 summarizes the
pharmacokinetics of oxoenoxacin in each patient group.
Renal dysfunction was associated with higher concentra-
tions of oxoenoxacin in serum. The AUCO_24 for oxoenoxa-
cin in groups 1 to 4 differed significantly from those observed
in patients with normal renal function; the higher AUCs in
each patient group reflect changes in both metabolite forma-
tion as well as elimination. Plots of the ratio of oxoenoxacin:
enoxacin concentration versus time were convex for all
patients, indicating that the rate of metabolite formation was
rate limiting in patients with normal as well as decreased
renal functions (5).
Figure 3 depicts the linear relationship between creatinine
clearance and renal oxoenoxacin clearance. As with enoxa-
cin, oxoenoxacin renal clearance in groups 2 and 3 (creati-
nine clearance, less than 30 ml/min) was significantly less
than that observed in patients with creatinine clearances
exceeding 60 ml/min (Table 4).
Table 3 shows the urinary excretion of oxoenoxacin. The
urinary recovery of oxoenoxacin was significantly lower in
group 1 patients than in the other patients.
Hemodialysis. Figure 4 depicts enoxacin and oxoenoxacin
concentrations in serum in a patient who was on and off
hemodialysis. Comparison of the respective AUC,, 24 values
for three patients who were on and off dialysis demonstrated
that little enoxacin or oxoenoxacin was removed (Table 5);
this was confirmed, in that low concentrations of enoxacin
(.0.09 mg/liter) and oxoenoxacin (s0.28 mg/liter at 30 min
to c0.09 mg/liter at 240 min) were measured in the dialysate
collected over the dialysis period. An increase in oxoenox-
acin concentrations (redistribution) was observed following
dialysis in all three patients.
DISCUSSION
Studies in normal healthy volunteers demonstrated that
enoxacin excretion is balanced between the renal and non-
renal routes. Following a single oral dose of 600 mg orally
and an i.v. infusion of 400 mg, 61 and 46% of the doses,
respectively, were recovered unchanged in urine (11). Other
studies have reported urinary recovery to be between 44 and
60% (1, 2, 10; M. N. Dudley, Postgrad. Med., in press).
Metabolism of enoxacin occurs on the piperazine ring to
form oxo, amino, formyl, and acetyl derivatives; the major
metabolite is 4-oxoenoxacin (4 to 15% of the dose excreted
in urine (11, 12; Dudley, in press). Oxoenoxacin has antimi-
crobial activity that is 10 to 15 times less than that of the
parent drug (8).
The balance in elimination of enoxacin between the renal
and nonrenal routes results in the lack of significant changes
in enoxacin pharmacokinetics in patients with creatinine
clearances exceeding 30 ml/min. However, in patients with
creatinine clearances below 30 ml/min (i.e., groups 1 to 3),
the group mean values for the total clearance and half-life of
350
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FIG. 3. Relation between creatinine clearance (CLCR) and ox-
oenoxacin renal clearance (CLR.x.; CLROXO = 2.02 x CLCR; P <
0.05). A point (118, 730.8) was not included in the regression.
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FIG. 4. Enoxacin (0) and oxoenoxacin (@) concentrations in
serum in patient 2 after administration of 400 mg of enoxacin i.v. on
the day of hemodialysis (HD) (a) and on the day offhemodialysis (b).
enoxacin were significantly prolonged compared with those
of patients with creatinine clearances exceeding 60 ml/min.
Both renal ahd, notably, nonrenal enoxacin clearances were
significantly correlated with creatinine clearances. The re-
duction in nonrenal enoxacin clearance with reduced renal
function was unexpected, but was consistent with the finding
that the formation of the major metabolite oxoenoxacin
remained rate limiting for all patients. Our data are in general
agreement with those of previous studies of i.v. and oral
enoxacin administration in elderly patients (6) and patients
with renal dysfunction given a single oral dose (7). Even in
the presence of severe renal dysfunction, urinary concentra-
tions of enoxacin exceeded the MICs for most susceptible
pathogens, even up to 72 h after administration of a single
dose.
In contrast to enoxacin, oxoenoxacin elimination was
variably but, on average, lower in patients with milder
degrees of renal dysfunction, with marked changes in renal
clearance being present as the creatinine clearance fell below
30 milmin; this is consistent with the fact that renal excretion
is the major route of elimination of the metabolite.
In limited studies of three patients undergoing hemodial-
ysis, minimal amounts of enoxacin and oxoenoxacin were
found in dialysates; intrapatient comparisons of the serum
AUCo_24 values confirmed this low extraction. Although
clearance of drug by hemodialysis could not be calculated,
the low levels of the drug with expected flow rates of
TABLE 5. AUCO24 for enoxacin or oxoenoxacin for three group
1 patients on and off hemodialysis
AUC-24 (mg h/liter)
Patient
no. Enoxacin Oxoenoxacin
On dialysis Off dialysis On dialysis Off dialysis
2 44.2 55.14 32.5 41.6
3 22.7 31.6 33.4 29.8
4 27.1 34.3 21.2 22.3
TABLE 6. Recommended alterations in enoxacin dosage
according to degree of renal impairment
CLCR Dosage regimen Cay, (mg/liter(ml/min)" [95% Cl])b
80 400 mg every 12 h 1.65 (1.4-2.0)
50 400 mg every 12 h 2.28 (1.9-2.8)
30 400 mg every 12 h 3.04 (2.4-4.0)
30 400 mg every 24 h 1.57 (1.2-2.0)
10 200 mg every 24 h 1.17 (0.8-2.0)
a CLCR, Creatinine clearance.
bCalculated as Ca.g (average concentration) - (dose/dosing interval)/[(3.1
x CLCR) + 881; the 95% confidence intervals (CI) in parentheses are
population values.
between 300 and 500 ml/h suggest a maximum removal of
only 10 to 20 mg of drug. The low extraction of enoxacin
(and other fluoroquinolones) is consistent with the finding
that most of the drug is distributed to extravascular sites in
the body and, thus, is not available for extraction during
dialysis (4; Dudley, in press). Comparison of group mean
values indicated that as the creatinine clearance falls below
30 ml/min, the daily enoxacin dose should be reduced by
half; since high peak concentrations of fluoroquinolones may
be linked to improved antibacterial effects and reduced
selection of resistant bacteria (Dudley, in press), it is recom-
mended that the usual dose be administered once daily
(Table 6). With a further decrement in renal function (creat-
inine clearance, less than 10 to 15 ml/min), half of the usual
dose should be given once daily. It should be noted, how-
ever, that accumulation of oxoenoxacin will likely occur
even with these dosage alterations. The clinical conse-
quences of oxoenoxacin accumulation are unknown.
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